Company Active LTD

Company profile

Ascension Healthcare Development Limited

Ascension

Ascension Healthcare Development Limited is a UK company with status active founded in 2012 based in London.

CRN
08217622
Founded
2012
Age
13

Overview

Legal name
ASCENSION HEALTHCARE DEVELOPMENT LIMITED
Region
London
Registered address
C/O ALIXPARTNERS UK LLP
6 NEW STREET SQUARE
LONDON
EC4A 3BF
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active LTD
Ascension Healthcare Development Limited
CRN 08217622
2
Direct and ultimate controller Active PLC

Company events

Reference milestones and recent Companies House filing stream events.

8 events
01 Oct
2025

Confirmation statement due

Confirmation Due

Next confirmation statement due date

14 Nov
2024

Liquidation In Administration Appointment Of Administrator

Insolvency

AM01 | Transaction MzQ0MjY4OTM4M2FkaXF6a2N4 | Paper/PDF filed

Published 19 Nov 2024 01:25

14 Nov
2024

Change Registered Office Address Company With Date Old Address New Address

Address

AD01 | Transaction MzQ0MjY4OTU4NGFkaXF6a2N4 | Paper/PDF filed

Published 19 Nov 2024 01:12

30 Oct
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQ0MTIyODEzMmFkaXF6a2N4

Published 30 Oct 2024 11:34

17 Sep
2024

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Sep
2023

Accounts due

Accounts Due

Next accounts due date

31 Dec
2021

Accounts filed

Accounts

Last accounts made up date

17 Sep
2012

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2017
Funded years
2017
Age at first award
4 years

Projects

2017 Collaborative R&D Lead participant

A polymyxin-based potentiator for treatment of MDR Gram-negative bacterial infections

1 Jan 2017 to 31 Dec 2018

Awarded
£800,437
Total cost £1,143,482

The O'Neill report identifies antibiotic resistance as one of the most important issues threatening our way of life. The potential consequences of failure to address this threat are assessed as 10 million deaths per annum by 2050 at an economic cost of 100 trillion US dollars. This project addresses one of the most difficult to treat classes of bacterial ...

Product types

Collaborative R&D